Single Cell Landscape of HBV-related Acute-on-chronic Liver Failure Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to profile the peripheral blood immune cells of patients with HBV related acute-on-chronic liver failure using single-cell RNA sequencing to reveal the immunopathological mechanisms of HBV related acute-on-chronic liver failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Albumin Modifications as Early Biomarkers of Chronic Liver Diseases

NCT06318949

Chronic Liver Disease

RECRUITING NA

S100A8/A9 and Innate Immunity in Liver Disease

NCT05793983

Cirrhosis, Liver Immune Suppression Liver Failure, Acute on Chronic +2 more

UNKNOWN

Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure

NCT05909319

Acute-On-Chronic Liver Failure

UNKNOWN

Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease

NCT00610597

Alcoholic Liver Disease Chronic Hepatitis C Virus

COMPLETED

Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis

NCT00160940

Hepatitis C Hepatitis B Autoimmune Hepatitis +2 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute-on-chronic liver failure (ACLF) is a complex clinical syndrome characterized by acute deterioration of liver function in patients with chronic liver disease, exhibiting liver and extrahepatic organ failure and a high short-term mortality. Immune imbalance plays an important role in the progression of HBV-related ACLF. Further investigation of the immune cell characteristics of HBV-related ACLF is helpful to understand its pathogenesis, and may provide reference for the effective therapeutic agent. Single-cell RNA sequencing (scRNA-seq) is the quantitative analysis of transcription at the single-cell level, which could provide systematic analyses of transcriptomic profiles, infer cell-cell interactions. This study will combine single cell transcriptomics and molecular biological experiment to elucidate the immunopathological cell states associated with HBV-related chronic liver disease vs. ACLF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HBV Related Acute-on-chronic Liver Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic Hepatitis B

No interventions assigned to this group

HBV related liver cirrhosis

No interventions assigned to this group

HBV related acute-on-chronic hepatic dysfunction

No interventions assigned to this group

HBV related acute-on-chronic liver failure

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Acute liver failure is a well-defned medical emergency which is defned as a severe liver injury, leading to coagulation abnormality usually with an INR ≥ 1.5, and any degree of mental alteration (encephalopathy) in a patient without pre-existing liver disease and with an illness of up to 4 weeks duration

Exclusion Criteria

* Associated with other types of hepatitis virus infection or HIV infection, alcoholic liver disease, autoimmune liver disease, drug-induced liver injury; ② Suffering from primary liver cancer or severe heart, digestive, lung, kidney, neurological and psychiatric diseases; ③ Patients with incomplete data and patients unable to participate in the experiment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No